Up to 80% of patients admitted to Intensive Care Units (ICUs) develop some form of neuromuscular dysfunction, which often leads to a much more serious complication known as ICU Acquired Weakness (ICUAW). ICUAW is a global muscle weakness that can develop in as little as a few hours after admission to the ICU and results in prolonged hospital stays (both in the ICU and afterwards in the ward), increased healthcare costs and reductions in health-related quality of life and expectancy.
of US ICU patients are at risk of developing ICUAW each year
Increased cost to US Healthcare System due to ICUAW in mechanically ventilated patients
Health Discovery Labs has been developing a revolutionary Electrical Muscle Stimulation (EMS) system called MyokinE, which provides a non-volitional exercise strategy (i.e., a muscle stimulation therapy that can be administered to unconscious patients) primarily intended for use with critically-ill patients who are at risk of developing ICUAW. On average, the MyokinE system will reduce the length of stay in the ICU by 1.6 days for mechanically ventilated patients.
Based on average ICU day cost of $7,453 (starting in day 3)
and on non-ICU day cost of $2,166
Nephrologist specializing in kidney diseases, dialysis, and organ transplantation
LinkedIn
